Lilly Settles U.S. SEC Allegations Its Units Paid Bribes In China, Russia
This article was originally published in PharmAsia News
Executive Summary
Eli Lilly has settled a dispute with the U.S. Securities and Exchange Commission, agreeing to pay more than $29 million for alleged bribery by its subsidiaries in China, Russia, Brazil and Poland.